<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240080</url>
  </required_header>
  <id_info>
    <org_study_id>19-011561</org_study_id>
    <nct_id>NCT04240080</nct_id>
  </id_info>
  <brief_title>Impact of Near-Infrared Vein Mapping on Outcomes and Satisfaction After Botox/Filler Treatment</brief_title>
  <official_title>The Impact of Near-Infrared Vein Mapping on Outcomes and Satisfaction After Botox/Filler Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are studying how vein mapping impacts patient outcomes and satisfaction after
      facial injection procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Facial Botox/filler injections carry risk of puncturing superficial veins, leading to
      bruising and pain. Our study will investigate the utility of non-invasive vein imaging
      (specifically near-infrared light reflection) on the incidence of pain/bruising/hematoma and
      patient satisfaction after facial injections.

      The current standard of care for facial injection procedures does not involve any modality of
      facial venous mapping. Vein mapping is a non-invasive, simple task that takes very little
      time to conduct. One risk is patient time, however maximum extra time needed will be 5
      minutes during the clinical visit. This potential extra time in mind, the benefits far
      outweigh the risks.

      Two cohorts of patients will be prospectively compared following randomization, those who did
      have pre-procedure venous mapping prior to injection versus those who did not. Data will be
      analyzed with regard to bruising and swelling following injection, as well as other potential
      complications such as hematoma or infection, along with patient satisfaction survey
      information.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Approximately 7-10 days following the procedure</time_frame>
    <description>Measured using the self-reported FACE-Q satisfaction score, using a scale of 1=definitely disagree and 4=definitely agree</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Bruising/Hematoma</measure>
    <time_frame>Approximately 7-10 days following the procedure</time_frame>
    <description>Number of subjects to experience bruising/hematoma post facial injection procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Wrinkle</condition>
  <arm_group>
    <arm_group_label>Control Goup</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will undergo clinically indicated facial injection procedures per standard of care without venous mapping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo clinically indicated facial injection procedure with pre-procedural facial venous mapping by Accuvein® Veinfinder</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accuvein® Veinfinder</intervention_name>
    <description>Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients pursuing aesthetic/therapeutic facial injection procedures (botox/filler)

        Exclusion Criteria:

          -  Patients undergoing aesthetic facial procedures not requiring needle injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Casey III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Casey, MD</last_name>
    <phone>480-342-2976</phone>
    <email>Casey.williamjoseph@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob Hammond, MD</last_name>
    <phone>480-342-2000</phone>
    <email>Hammond.jacob@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Casey, MD</last_name>
      <phone>480-342-2976</phone>
      <email>Casey.williamjoseph@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>William J. Casey, III</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

